Introduction: Early detection of patients with advanced chronic liver disease is critical for the prevention of complications and inclusion in surveillance programs for hepatocellular carcinoma. In daily clinical care, it remains challenging to differentiate early cirrhosis from lower fibrosis grades without performing a liver biopsy. The aim of the present study was to assess the performance of different non-invasive detection tools to differentiate cirrhosis from lower fibrosis grades. Methods: Data of 116 patients (51 male, 65 female) with chronic liver disease of various origins undergoing liver biopsy was analyzed. Routine laboratory values, liver stiffness measurement (LSM) by transient elastography, and histological liver assessment were collected. Results: Robust and significant correlations with the histological fibrosis stage were identified for LSM (r = 0.65), the FAST score (0.64), the FIB-4 (0.48), serum aspartate aminotransferase (AST) concentration (0.41), NFS (0.33), international normalized ratio (INR; 0.30), methacetin breath test results (−0.40), and serum albumin concentration (−0.29) by spearman rank correlation. Receiver operating characteristic curves were built for these parameters to separate patients with cirrhosis from those with any other fibrosis stage. The highest AUC was achieved by LSM (0.9130), followed by the FAST score (0.8842), the FIB-4 (0.8644), the NFS (0.8227), INR (0.8142), serum albumin (0.7710), and serum AST (0.7620). The most promising clinical applicability would be an LSM value of 12.2 kPa, achieving 95.7% sensitivity and 75.3% specificity. Conclusion: LSM and FAST score seem to be robust non-invasive measurements for liver fibrosis. LSM and FAST scores may have the potential to reliably detect patients with liver cirrhosis in clinical routine settings.

1.
Wynn
TA
.
Cellular and molecular mechanisms of fibrosis
.
J Pathol
.
2008
;
214
(
2
):
199
210
.
2.
GBD 2017 Cirrhosis Collaborators
.
The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
.
Lancet Gastroenterol Hepatol
.
2020
;
5
(
3
):
245
66
.
3.
D’Amico
G
,
Garcia-Tsao
G
,
Pagliaro
L
.
Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies
.
J Hepatol
.
2006
;
44
(
1
):
217
31
.
4.
Cheemerla
S
,
Balakrishnan
M
.
Global epidemiology of chronic liver disease
.
Clin Liver Dis
.
2021
;
17
(
5
):
365
70
.
5.
Vilar-Gomez
E
,
Chalasani
N
.
Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers
.
J Hepatol
.
2018
;
68
(
2
):
305
15
.
6.
Powell
EE
,
Wong
VW
,
Rinella
M
.
Non-alcoholic fatty liver disease
.
Lancet
.
2021
;
397
(
10290
):
2212
24
.
7.
Mózes
FE
,
Lee
JA
,
Selvaraj
EA
,
Jayaswal
ANA
,
Trauner
M
,
Boursier
J
, et al
.
Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis
.
Gut
.
2022
;
71
(
5
):
1006
19
.
8.
Byrne
CD
,
Targher
G
.
NAFLD: a multisystem disease
.
J Hepatol
.
2015
;
62
(
1 Suppl l
):
S47
64
.
9.
Dulai
PS
,
Singh
S
,
Patel
J
,
Soni
M
,
Prokop
LJ
,
Younossi
Z
, et al
.
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis
.
Hepatology
.
2017
;
65
(
5
):
1557
65
.
10.
Paik
JM
,
Kabbara
K
,
Eberly
KE
,
Younossi
Y
,
Henry
L
,
Younossi
ZM
.
Global burden of NAFLD and chronic liver disease among adolescents and young adults
.
Hepatology
.
2022
;
75
(
5
):
1204
17
.
11.
Papatheodoridi
M
,
Hiriart
JB
,
Lupsor-Platon
M
,
Bronte
F
,
Boursier
J
,
Elshaarawy
O
, et al
.
Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease
.
J Hepatol
.
2021
;
74
(
5
):
1109
16
.
12.
Sanyal
AJ
,
Van Natta
ML
,
Clark
J
,
Neuschwander-Tetri
BA
,
Diehl
A
,
Dasarathy
S
, et al
.
Prospective study of outcomes in adults with nonalcoholic fatty liver disease
.
N Engl J Med
.
2021
;
385
(
17
):
1559
69
.
13.
Sarin
SK
,
Kumar
M
,
Eslam
M
,
George
J
,
Al Mahtab
M
,
Akbar
SMF
, et al
.
Liver diseases in the asia-pacific region: a lancet gastroenterology & hepatology commission
.
Lancet Gastroenterol Hepatol
.
2020
;
5
(
2
):
167
228
.
14.
Singal
AG
,
El-Serag
HB
.
Rational HCC screening approaches for patients with NAFLD
.
J Hepatol
.
2022
;
76
(
1
):
195
201
.
15.
Singal
AG
,
Zhang
E
,
Narasimman
M
,
Rich
NE
,
Waljee
AK
,
Hoshida
Y
, et al
.
HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: a meta-analysis
.
J Hepatol
.
2022
;
77
(
1
):
128
39
.
16.
Graupera
I
,
Thiele
M
,
Serra-Burriel
M
,
Caballeria
L
,
Roulot
D
,
Wong
GL
, et al
.
Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population
.
Clin Gastroenterol Hepatol
.
2022
;
20
(
11
):
2567
76.e6
.
17.
European Association for the Study of the Liver Electronic address easloffice@easlofficeeu
;
Clinical Practice Guideline PanelChair
;
EASL Governing Board representative
;
Panel members
.
EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update
.
J Hepatol
.
2021
;
75
(
3
):
659
89
.
18.
Mikolasevic
I
,
Orlic
L
,
Franjic
N
,
Hauser
G
,
Stimac
D
,
Milic
S
.
Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - where do we stand
.
World J Gastroenterol
.
2016
;
22
(
32
):
7236
51
.
19.
Younossi
ZM
,
Koenig
AB
,
Abdelatif
D
,
Fazel
Y
,
Henry
L
,
Wymer
M
.
Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes
.
Hepatology
.
2016
;
64
(
1
):
73
84
.
20.
Siddiqui
MS
,
Vuppalanchi
R
,
Van Natta
ML
,
Hallinan
E
,
Kowdley
KV
,
Abdelmalek
M
, et al
.
Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease
.
Clin Gastroenterol Hepatol
.
2019
;
17
(
1
):
156
63.e2
.
21.
Siddiqui
MS
,
Yamada
G
,
Vuppalanchi
R
,
Van Natta
M
,
Loomba
R
,
Guy
C
, et al
.
Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage
.
Clin Gastroenterol Hepatol
.
2019
;
17
(
9
):
1877
85.e5
.
22.
Newsome
PN
,
Sasso
M
,
Deeks
JJ
,
Paredes
A
,
Boursier
J
,
Chan
WK
, et al
.
FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study
.
Lancet Gastroenterol Hepatol
.
2020
;
5
(
4
):
362
73
.
23.
Updated S2k clinical practice guideline on non-alcoholic fatty liver disease (NAFLD) issued by the German society of gastroenterology, digestive and metabolic diseases (DGVS) - april 2022 - AWMF registration No.: 021-025
.
Z für Gastroenterologie
.
2022
.
60
(
09
):
e733
801
.
24.
Yokoo
T
,
Serai
SD
,
Pirasteh
A
,
Bashir
MR
,
Hamilton
G
,
Hernando
D
, et al
.
Linearity, bias, and precision of hepatic proton density fat fraction measurements by using MR imaging: a meta-analysis
.
Radiology
.
2018
;
286
(
2
):
486
98
.
25.
Loomba
R
,
Adams
LA
.
Advances in non-invasive assessment of hepatic fibrosis
.
Gut
.
2020
;
69
(
7
):
1343
52
.
26.
Loomba
R
,
Wolfson
T
,
Ang
B
,
Hooker
J
,
Behling
C
,
Peterson
M
, et al
.
Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study
.
Hepatology
.
2014
;
60
(
6
):
1920
8
.
27.
Ajmera
V
,
Loomba
R
.
Imaging biomarkers of NAFLD, NASH, and fibrosis
.
Mol Metab
.
2021
;
50
:
101167
.
28.
Ferraioli
G
,
Roccarina
D
.
Update on the role of elastography in liver disease
.
Therap Adv Gastroenterol
.
2022
;
15
:
17562848221140657
.
29.
Dietrich
CF
,
Bamber
J
,
Berzigotti
A
,
Bota
S
,
Cantisani
V
,
Castera
L
, et al
.
EFSUMB guidelines and recommendations on the clinical use of liver ultrasound elastography, update 2017 (long version)
.
Ultraschall Med
.
2017
;
38
(
4
):
e16
e47
.
30.
Bedossa
P
,
Dargère
D
,
Paradis
V
.
Sampling variability of liver fibrosis in chronic hepatitis C
.
Hepatology
.
2003
;
38
(
6
):
1449
57
.
31.
Lidbury
JA
.
Getting the most out of liver biopsy
.
Vet Clin North Am Small Anim Pract
.
2017
;
47
(
3
):
569
83
.
32.
Crawford
AR
,
Lin
XZ
,
Crawford
JM
.
The normal adult human liver biopsy: a quantitative reference standard
.
Hepatology
.
1998
;
28
(
2
):
323
31
.
33.
Neuberger
J
,
Patel
J
,
Caldwell
H
,
Davies
S
,
Hebditch
V
,
Hollywood
C
, et al
.
Guidelines on the use of liver biopsy in clinical practice from the British society of gastroenterology, the royal college of radiologists and the royal college of pathology
.
Gut
.
2020
;
69
(
8
):
1382
403
.
You do not currently have access to this content.